These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 8043939)

  • 1. Management of older adults with hypercholesterolaemia.
    Pacala JT; McBride PE; Gray SL
    Drugs Aging; 1994 May; 4(5):366-78. PubMed ID: 8043939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of hypercholesterolaemia in postmenopausal women.
    Davidson MH; Maki KC; Karp SK; Ingram KA
    Drugs Aging; 2002; 19(3):169-78. PubMed ID: 12027776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypercholesterolaemia in the elderly: is drug treatment justified?
    Tikkanen MJ
    Eur Heart J; 1988 Mar; 9 Suppl D():79-82. PubMed ID: 3378558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia.
    Malhotra HS; Goa KL
    Drugs; 2001; 61(12):1835-81. PubMed ID: 11693468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.
    Evans M; Roberts A; Davies S; Rees A
    Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is it advantageous to lower cholesterol in the elderly hypertensive?
    Beckett N; Nunes M; Bulpitt C
    Cardiovasc Drugs Ther; 2000 Aug; 14(4):397-405. PubMed ID: 10999646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of hypercholesterolaemia in the patient with diabetes.
    Packard C; Olsson AG
    Int J Clin Pract Suppl; 2002 Jul; (130):27-32. PubMed ID: 12296606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cholesterol lowering in the elderly population. Coordinating Committee of the National Cholesterol Education Program.
    Grundy SM; Cleeman JI; Rifkind BM; Kuller LH
    Arch Intern Med; 1999 Aug 9-23; 159(15):1670-8. PubMed ID: 10448768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment challenges in hypercholesterolemia.
    Pauciullo P; Mancini M
    Cardiovasc Drugs Ther; 1998 Sep; 12(4):325-37. PubMed ID: 9825176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The cost-effectiveness of HMG-CoA reductase inhibitors to prevent coronary heart disease. Estimating the benefits of increasing HDL-C.
    Hamilton VH; Racicot FE; Zowall H; Coupal L; Grover SA
    JAMA; 1995 Apr; 273(13):1032-8. PubMed ID: 7897787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Therapy and prevention of coronary heart diseases through lowering of the serum cholesterol levels; third consensus 'Cholesterol'. Consensus Working Group, CBO].
    Simoons ML; Casparie AF
    Ned Tijdschr Geneeskd; 1998 Sep; 142(38):2096-101. PubMed ID: 9856223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of fibric acid derivatives in the management of risk factors for coronary heart disease.
    Després JP; Lemieux I; Robins SJ
    Drugs; 2004; 64(19):2177-98. PubMed ID: 15456334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypercholesterolemia in elderly persons: resolving the treatment dilemma.
    Denke MA; Grundy SM
    Ann Intern Med; 1990 May; 112(10):780-92. PubMed ID: 2184712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypercholesterolemia. Is lipid-lowering worthwhile for older patients?
    Deedwania PC
    Geriatrics; 2000 May; 55(5):22-8. PubMed ID: 10826262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cholesterol: precursor to many lipid disorders.
    Jones PH
    Am J Manag Care; 2001 Aug; 7(9 Suppl):S289-98. PubMed ID: 11517815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.
    Plans-Rubió P
    Am J Cardiovasc Drugs; 2006; 6(3):177-88. PubMed ID: 16780391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effectiveness and tolerability of simvastatin in patients with moderate-to-severe hypercholesterolemia. Results of a 12-month study].
    Ghizzoni G; Rusconi C; Faggiano P; Sabatini T; Oneglia C; Gardini A
    Minerva Cardioangiol; 1993 Mar; 41(3):105-9. PubMed ID: 8510811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment potential for dyslipidaemia management in patients with coronary heart disease across Europe: findings from the EUROASPIRE III survey.
    Reiner Ž; De Bacquer D; Kotseva K; Prugger C; De Backer G; Wood D;
    Atherosclerosis; 2013 Dec; 231(2):300-7. PubMed ID: 24267243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current, new and future treatments in dyslipidaemia and atherosclerosis.
    Chong PH; Bachenheimer BS
    Drugs; 2000 Jul; 60(1):55-93. PubMed ID: 10929930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and validation of a model to project the long-term benefit and cost of alternative lipid-lowering strategies in patients with hypercholesterolaemia.
    Cook JR; Yin D; Alemao E; Drummond M
    Pharmacoeconomics; 2004; 22 Suppl 3():37-48. PubMed ID: 15669152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.